Blood is a living tissue made up of fluid, with various cells and proteins suspended in it. It is a coursing liquid, containing red platelets, white platelets, and platelets. It gives oxygen and food to the body cells through vessels, conductors, and veins. It additionally expels metabolic waste and carbon dioxide from the body. A blood screening is a therapeutic procedure in which blood is analyzed for a particular illness or condition. It screens ailments and prevent medicinal issues and a combination of various conditions, for instance, maladies and danger. Blood screening is a medicinal procedure in which given blood is mostly tried for HIV1, HIV2, HBV, HCV, jungle fever, syphilis, and different irresistible ailments. Given blood is screened for these irresistible illnesses to lessen the danger of transfusion-transmitted contaminations (TTIs). The worldwide blood screening market comprises of different advances and items and administrations which are utilized as a part of blood donation centers and doctor’s facilities for the screening of different TTIs.
How Big is the global Blood Screening Market?
The Blood Screening Market is expected to be around US$ 4.80 Billion by 2028 at a CAGR of 9.7% in the given forecast period.
The major driving factors of Blood Screening Market are as follows:
The restraining factors of Blood Screening Market are as follows:
The Blood Screening Market is segmented on the lines of its product, service, technology, end user and regional. Based on product, services segmentation it coversreagents & kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, labeling and detection reagents, immunosorbents, controls, conjugates, substrates, sample diluents and wash solutions, instruments, software and services. Based on technology segmentation it covers nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS). Based on end user segmentation it covers blood banks, hospitals.The Blood Screening Marketon geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Blood Screening Market and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Blood Screening Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets onBlood Screening Marketwith the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Grifols (Spain), Dickinson and Company (U.S.), Roche Diagnostics (Switzerland), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Siemens Healthineers (Germany), and bioMérieux (France).Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Blood Screening Market has been segmented as below : (Accordingly)
By Technology Analysis:
By End User Analysis:
By Product/Services Analysis:
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Blood Screening Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Blood Screening Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our new reports:
Exosome Diagnostic and Therapeutics market
Extracorporeal shock wave Lithotripter market
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown & Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Conclusion
4 Premium Insights
4.1 Blood Screening Market
4.2 Blood Screening Market, By Region & Technology
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Number of Blood Donations and Blood Donors
5.2.1.2 Increasing Demand of Donated Blood
5.2.1.3 Rising Prevalence of Infectious Diseases
5.2.1.4 Growing Affordability and Adoption of NAT for Blood Screening
5.2.1.5 Rising Awareness Regarding the Safety of Donated Blood
5.2.2 Restraints
5.2.2.1 Capital Expenditure and Operating Costs of NAT
5.2.2.2 Lack of Regulations Mandating the Use of NAT in Developing Countries
5.2.2.3 Emergence of Alternative Technologies
5.2.3 Opportunities
5.2.3.1 Pathogen Reduction Technology
5.2.3.2 Multiplex Tests
5.2.3.3 Emerging Economies
5.2.4 Challenges
5.2.4.1 Price Reduction
6 Blood Screening Market, By Technology
6.1 Introduction
6.2 Blood Screening Market, By Volume (Number of Tests Conducted)
6.3 Nucleic Acid Test (NAT)
6.3.1 Transcription-Mediated Amplification (TMA)
6.3.2 Real-Time Polymerase Chain Reaction (PCR)
6.4 Enzyme-Linked Immunosorbent Assay (ELISA)
6.4.1 ELISA Market, By Platform
6.4.1.1 Chemiluminescence Immunoassay (CLIA)
6.4.1.2 Fluorescence Immunoassay (FIA)
6.4.1.3 Colorimetric Immunoassay (CI)
6.4.2 ELISA Market, By Generation
6.4.2.1 First-Generation ELISA
6.4.2.2 Second-Generation ELISA
6.4.2.3 Third-Generation ELISA
6.4.2.4 Fourth-Generation & Above
6.5 Rapid Tests
6.6 Western Blot Assay
6.7 Next-Generation Sequencing (NGS)
7 Blood Screening Market, By Product and Service
7.1 Introduction
7.2 Reagents & Kits
7.2.1 NAT Reagents & Kits
7.2.1.1 Enzymes and Polymerases
7.2.1.2 Standards and Controls
7.2.1.3 Probes and Primers
7.2.1.4 Buffers, Nucleotides and Solutions
7.2.1.5 Labeling and Detection Reagents
7.2.2 ELISA Reagents & Kits
7.2.2.1 Immunosorbents
7.2.2.2 Controls
7.2.2.3 Conjugates (Antigen Or Antibody-Conjugated Enzyme)
7.2.2.4 Substrates (Of Enzymes)
7.2.2.5 Sample Diluents and Wash Solutions
7.2.3 Other Reagents
7.3 Instruments
7.3.1 Rental Purchase
7.3.2 Outright Purchase
7.4 Software and Services
8 Blood Screening Market, By End User
8.1 Introduction
8.2 Blood Banks
8.3 Hospitals
9 Blood Screening Market, By Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe (RoE)
9.4 Asia
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Rest of Asia (RoA)
9.5 Rest of the World (RoW)
10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis
10.2.1 Market Share Analysis for NAT
10.2.2 Blood Screening Market Share Analysis
10.3 Competitive Situations and Trends
10.3.1 Product Launches
10.3.2 Regulatory Approvals
10.3.3 Agreements
10.3.4 Partnerships
10.3.5 Acquisitions
10.3.6 Expansions
11 Company Profiles
11.1 Introduction
11.2 Grifols
11.3 F. Hoffmann-La Roche
11.4 Abbott Laboratories
11.5 Biomérieux
11.6 Bio-Rad Laboratories, Inc.
11.7 Siemens Healthineers (A Subsidiary of Siemens AG)
11.8 Ortho Clinical Diagnostics, Inc.
11.9 Thermo Fisher Scientific, Inc.
11.10 Beckman Coulter (A Subsidiary of Danaher Corporation)
11.11 Becton, Dickinson and Company
The Blood Screening Market has been segmented as below : (Accordingly)
By Technology Analysis:
By End User Analysis:
By Product/Services Analysis:
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
SUBSCRIBE TO OUR NEWSLETTERS
